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The majority of malaria infections in low transmission settings remain undetectable
by conventional diagnostics. A powerful model to identify antibody responses that
allow accurate detection of recent exposure to low-density infections is controlled
human malaria infection (CHMI) studies in which healthy volunteers are infected with
the Plasmodium parasite. We aimed to evaluate antibody responses in malaria-naïve
volunteers exposed to a single CHMI using a custom-made protein microarray. All
participants developed a blood-stage infection with peak parasite densities up to 100
parasites/µl in the majority of participants (50/54), while the remaining four participants
had peak densities between 100 and 200 parasites/µl. There was a strong correlation
between parasite density and antibody responses associated with the most reactive
blood-stage targets 1 month after CHMI (Etramp 5, GLURP-R2, MSP4 and MSP1-
19; Spearman’s ρ = 0.82, p < 0.001). Most volunteers developed antibodies against
a potential marker of recent exposure: Etramp 5 (37/45, 82%). Our findings justify
validation in endemic populations to define a minimum set of antigens needed to detect
exposure to natural low-density infections.
Keywords: malaria, antibodies, exposure, controlled human malaria infection (CHMI), sero-surveillance, sero-
epidemiology
INTRODUCTION
The use of serological tests to measure antibodies against malaria has been advocated as an
adjunct approach to improve the detection of transmission dynamics (Corran et al., 2007; Stewart
et al., 2009; malERA Refresh Consultative Panel on Characterising the Reservoir and Measuring
Transmission, 2017). This is particularly useful in low transmission settings, where the detection
of low-density infections is a major challenge (Okell et al., 2009; Wu et al., 2015). Due to the
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longevity of antibody responses they cannot be used as a
diagnostic for current infections, but at the population-level,
when combined with age, they represent historical and recent
transmission (Drakeley et al., 2005; Corran et al., 2007; Stewart
et al., 2009). Antibody metrics are less influenced by fluctuations
in infection rates between seasons, and where infection rates fall
to near elimination, they can help determine whether there is
any remaining ongoing transmission. The discovery of antigenic
markers that correlate with recent microscopic infection shows
promise in the context of detecting recent malaria transmission
patterns more sensitively (i.e., up to 1 year) (Helb et al., 2015).
However, it remains largely unknown which antigens most
reliably induce measurable antibody responses to allow accurate
detection of recent exposure to low-density infections.
The identification of antibody responses, and their
corresponding antigen targets, following low-density infections
in endemic settings is challenging, as the history of previous
exposure is often difficult to determine. Longitudinal studies
have demonstrated the acquisition of antibodies following
asymptomatic infection in endemic areas and suggest that
antibodies to some antigens might be more sensitive markers
of recent exposure (McCallum et al., 2017). A powerful model
to examine this is using controlled human malaria infections
(CHMI) in which healthy volunteers are infected via mosquito
bites (Roestenberg et al., 2009), parenteral injection with
sporozoites (Bastiaens et al., 2016) or infected red blood
cells (Pombo et al., 2002). Parasite densities are monitored
intensely and remain low as treatment is provided either at
the first microscopy-detectable parasitemia, or even earlier
at levels detectable only by qPCR (Walk et al., 2016). CHMI
studies in non-endemic (reviewed in (Sauerwein et al., 2011))
and endemic (Shekalaghe et al., 2014; Hodgson et al., 2015)
settings generally aim to determine correlates of immune
protection or test vaccination strategies (Bastiaens et al.,
2016). Therefore, responses against mainly pre-erythrocytic
antigens have been studied (Felgner et al., 2013; Nahrendorf
et al., 2014; Peng et al., 2016), some of which have been
suggested as markers of recent parasite exposure (Nahrendorf
et al., 2014). However, few have studied antibody responses
in previously naïve control groups and only a small number
of antigenic targets have been analyzed using enzyme-linked
immunosorbent (ELISA) or multiplex bead assays (Turner et al.,
2011; Obiero et al., 2015; Hodgson et al., 2016; Burel et al.,
2017).
Protein microarrays enable the simultaneous detection
of antibody responses to hundreds of antigens to identify
biomarkers related to protection or exposure (Boyle et al., 2017).
Antigen production for these arrays have mostly used the in vitro
translation/transcription (IVTT) open reading frame (ORF)
method – a polymerase chain reaction (PCR)-based approach
that generates large numbers of putative proteins (Davies et al.,
2005). In this study, we use a custom-made protein microarray
based on purified recombinant malaria antigens which was
enriched for antigens associated with recent exposure. Using
this array, we aimed to identify immunogenic targets associated
with recent low-density Plasmodium falciparum infections in
previously malaria-naïve CHMI participants.
MATERIALS AND METHODS
Study Population
Fifty-four malaria naïve participants [based on patient history
and lack of antibody responses to asexual parasite lysate
(Walk et al., 2017)] from eight CHMI studies were included
(Supplementary Table S1). The study population and sampling
frame have been described in detail elsewhere (Bijker et al.,
2013, 2014a,b; Bastiaens et al., 2016; Walk et al., 2017; Reuling
et al., 2018). In short, volunteers were infected by exposure
to five laboratory reared Anopheles mosquitoes infected with
P. falciparum sporozoites of the well characterized NF54 strain,
its clone 3D7, or the more recently characterized NF135.C10
(Teirlinck et al., 2013) or NF166.C8 (McCall et al., 2017) strains.
Citrate plasma samples for antibody detection were selected at
three time points: 1 day pre-challenge (C−1), 21 or 35 days after
challenge (median 30 days; C+30) and 64, 140, or 213 days after
challenge (median 115 days; C+115). All available samples were
analyzed.
Ethics Statement
All clinical trials were carried out in accordance with Good
Clinical Practice guidelines and were prospectively registered
at ClinicalTrials.gov (NCT numbers listed in Supplementary
Table S1). All subjects gave written informed consent prior to
participation in accordance with the Declaration of Helsinki.
Each clinical trial protocol was approved by the Central
Committee on Research Involving Human Subjects (CCMO) of
the Netherlands (reference numbers listed in Supplementary
Table S1). Study 8 was also approved by the Western Institutional
Review Board (WIRB) in the United States.
Parasite Detection
Volunteers were monitored for the development of symptoms
and blood-stage parasites once or twice daily after infection.
In studies 1–4 and 8 (Supplementary Table S1) parasitemia
was treated when detectable by thick blood smear. Blood
smears were read according to a standardized protocol for
CHMI studies (Bijker et al., 2014a), in which slides are scored
as positive if at least two parasites were seen in 0.5 µl of
blood (threshold of ∼4 parasites/µl). A second independent
microscopist confirmed positivity. In these studies qPCR was
performed on all blood samples according to a previously
published protocol (Schats et al., 2015). In studies 5–7, qPCR
was performed prospectively, and volunteers were treated
when parasitemia reached the predetermined threshold of 0.1
parasites/µl (Walk et al., 2016). In study 8, some volunteers
had a recrudescent infection after initial subcurative treatment
(Reuling et al., 2018).
Protein Microarray
The IgG responses to 40 antigenic targets, all blood-stage related
except for one (CSP), were determined using a custom-made
protein microarray (see Supplementary Table S2 for antigen
details). Protein preparations at a concentration of 100 µg/µl
of protein in printing buffer (ArrayJet, Scotland) were spotted
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onto nitrocellulose coated slides (Grace Bio-Labs, United States)
with a glycerol-based buffer using the ArrayJet Marathon printer
(ArrayJet, Scotland) at the London School of Hygiene and
Tropical Medicine (LSHTM). Each slide was sub-divided into
16 arrays with each array consisting of the full complement of
antigenic targets printed in duplicate. A standard curve of total
human IgG was printed in duplicate within each array (starting
concentration 200 µg/ml, fivefold series of 6 points). Samples
were processed for IgG detection at the Radboud University
Medical Center in Nijmegen. Serum samples were diluted in
a deep well at 1:200 in blocking buffer [Phosphate buffered
saline (PBS)/BlockIt buffer (ArrayIt Corporation, United States)
25%]. The printed nitrocellulose slides were placed in multi-well
hybridization cassettes (HC; ArrayIt Corporation, United States),
blocked with 200 µl of blocking buffer and incubated on a rotary
shaker (100 rpm) at room temperature (RT) for 1 h. Slides were
washed three times: liquid was removed by sharply flicking buffer
into a sink, then 200 µl of wash buffer (PBS/Tween 0.05%) was
immediately added and the HC placed on the rotary shaker for
2 min. After the final wash, wash buffer was aspirated using
a multichannel pipette one column at the time and 100 µl
of test samples was added immediately to avoid drying of the
nitrocellulose slides. Participant samples, two positive control
pools of hyper-immune sera (three repeats of a Ugandan and
four repeats of a Tanzanian pool) and one blank (i.e., blocking
buffer only) were distributed over twelve slides. Time points from
the same participants were grouped on slides where possible to
avoid influences of inter-slide variability during assay processing.
Slides were incubated for 1 h at RT on the rotary platform.
Slides were washed again three times and IgG-specific goat anti-
human secondary antibody (Alexa Fluor 633 goat anti-human
IgG; Invitrogen) was added in the same manner as the samples
at a concentration of 1:1000. Slides were incubated for 1 h at RT
on the rotary platform. After a further three washes, slides were
dried by centrifuging them at 3000 rpm for 5 min at RT. Slides
were stored at +4◦C and read 3 days after assay processing at
LSHTM using the GenePix 4300A scanner (Molecular Devices,
United States) at a wavelength of 635 nm.
Median fluorescence intensity (MFI) was background-
corrected (i.e., local reactivity around the spot; bkg) and duplicate
measurements were averaged (Pearson’s correlation coefficient
0.99, p < 0.001; Supplementary Figure S1). MFI-bkg values
smaller than or equal to zero, were replaced with the average value
of blank responses and log-transformed. Printing variability was
minimal, as determined by the coefficient of variation (CV) of the
third point of the standard IgG curve. Inter-slide variability was
measured at 1.4% CV, while intra-slide variability was measured
at<2.5%. Likewise, assay variability was minimal as shown by the
CV of repeated MFI-bkg values of the positive control pools on
different slides for GLURP-R2, MSP4 and CSP (associated with
high, medium and low antibody responses): 1.5, 0.2, and 5.5% for
the Tanzanian pool (n = 4), and 0.5, 0.3, and 4.2% for the Ugandan
pool (n = 3).
Statistical Analyses
All statistical analyses were performed in STATA 14 and
PRISM 7. Cumulative parasite density was expressed as the log-
transformed area under the curve (AUC) for parasite density
versus time in days using the pkexamine command in STATA
with the trapezoid option. Only parasite density results up
to, and including, the day of curative antimalarial treatment
were included. Tertiles were used to categorize low, medium
and high cumulative parasite density. Antibody responses (IgG)
were expressed as log-transformed MFI-bkg values. The average
response of forty-five participants at C−1 plus two standard
deviations was used as the threshold for seropositivity by antigen.
Antibody responses at C+30 and C+115 were standardized by
subtracting the mean and dividing by the standard deviation
(SD) of C−1 responses. For both, one outlier at baseline for
Etramp 4 Ag 2 was removed (log-transformed MFI-bkg over
8). The Cochran-Armitage test was used to test the trend in
the proportion of antigenic targets recognized at each time
point over categories of cumulative parasite density. Spearman’s
rank coefficients (ρ) were used to assess the correlation between
antibody responses and cumulative parasite density. The level
of statistical significance for individual antigens was adjusted
according to the Bonferroni correction. Linear regression was
used to test the association between participant characteristics
and cumulative parasite density.
RESULTS
Cumulative Parasite Density and Peak
Parasite Density
All 54 CHMI participants developed a blood-stage infection after
sporozoite-induced challenge through infective mosquito bites
[median day of first blood-stage parasites detected by qPCR:
7.0, interquartile range (IQR) 6.5–7.0]. Parasitemias ranged from
peak parasite densities below 1 parasites/µl that were treated
7 days post-challenge, to peak densities of 198 parasites/µl that
were treated 14 days post-challenge, as well as recrudescent
infections that lasted 39 days post-challenge (Figures 1A–C). The
majority of individuals had peak parasite densities under 100
parasites/µl (50/54), with 19% under one parasite/µl (10/54).
A statistically significant difference in cumulative parasite density
(expressed as the log-transformed area under the curve for
parasite density versus time in days) was seen by gender
(p = 0.011), which disappeared after adjusting for study
(p = 0.861). The median age was 21 (IQR 19–22) and did not differ
between categories of parasite exposure (p = 0.541). As expected,
a statistically significant increase was seen in peak parasite density
with increasing cumulative parasite density (p < 0.001; Table 1
and Figure 1D). Participants with higher cumulative parasite
density experienced their peak parasite density later during their
infection (p< 0.001; Table 1).
Minimal Number of Antigens to Detect
Infection
The kinetics of IgG responses following challenge are shown
in Figure 2, while Figure 3A shows the number of antigenic
targets recognized before and after challenge per category of
cumulative parasite density. Two participants recognized more
than five out of the panel of 40 antigens pre-challenge (C−1);
1 month post-challenge (C+30) one of these two participants
Frontiers in Microbiology | www.frontiersin.org 3 January 2019 | Volume 9 | Article 3300
fmicb-09-03300 January 16, 2019 Time: 15:5 # 4
van den Hoogen et al. Antibody Responses Following Low-Density Infections
FIGURE 1 | Parasitemia after controlled human malaria infection over categories of cumulative parasite density (A–C) and associated peak parasite densities
(D). Tertiles of cumulative parasite density (expressed as the log-transformed area under the curve for parasite density versus time until, and including the day of
treatment) were used to categorize low (A), medium (B), and high (C). Peak parasite density is the maximum number of parasites/µl detected during the infection
until, and including the day of treatment.
TABLE 1 | Characteristics of the study population according to categories of cumulative parasite density.
All participants Categories of cumulative parasite density
Low Medium High
N 54 19 17 18
Time pointa (N)
−C−1 45 15 14 16
−C+30 45 17 14 14
−C+115 32 8 11 13
Cumulative parasite densityb median (IQR) 8.3 (7.0–9.8) 6.2 (4.6–7.4) 8.7 (8.2–9.2) 10.0 (9.8–10.7)
Peak parasite densityc median (IQR) 6.9 (2.0–31.6) 1.0 (0.3–2.4) 7.4 (5.1–19.1) 42.6 (22.7–75.4)
Day of peak parasite density median (IQR) 10.4 (7.0–12.3) 7.0 (7.0–9.3) 9.6 (7.0–11.5) 12.2 (10.6–13.5)
Categories of cumulative parasite density are based on tertiles of cumulative parasite density. IQR, interquartile range. aCitrate plasma samples for antibody detection
were selected at three time points: 1 day pre-challenge (C−1), 21 or 35 days after challenge (median 30 days; C+30) and 64, 140, or 213 days after challenge (median
115 days; C+115). All available samples were analyzed. bCumulative parasite density is expressed as the log-transformed area under the curve for parasites/µl versus time
in days until the day of treatment. One participant was not treated until day 36, however, this participant did not have a sample available at C+30 for antibody detection
thus their total cumulative parasite density was used for categorization in this table. cPeak parasite density is the maximum number of parasites/µl during the infection
until the day of treatment.
recognized two additional antigens (9 antigens in total) while
the other participant recognized thirteen additional antigens
(20 antigens in total). For all categories of cumulative parasite
density, the peak number of antigens recognized was at C+30.
The proportion of targets recognized increased over categories
of cumulative parasite density (p < 0.001 for C+30 and 2–
7 months post-challenge; C+115). High seroprevalence (i.e., over
80%) was seen against GLURP-R2 (91%, 41/45) and Etramp 5
Ag 1 (82%, 37/45) at C+30, and against MSP1-19 at C+115 (84%,
27/32). For participants with medium to high cumulative parasite
density, all were seropositive to GLURP-R2 and 96% to Etramp
5 Ag 1 (27/28) at C+30 (Supplementary Figure S2), and 96%
responded to MSP1-19 at C+115 (23/24). For the lowest category,
77% (13/17) responded to GLURP-R2 and 59% (10/17) to Etramp
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FIGURE 2 | Kinetics of antimalarial antibody responses after controlled human malaria infection. Antibody responses (expressed as log-transformed median
fluorescence intensity corrected for background reactivity) are shown over time, starting 1 day pre-challenge. Red dashed lines represent thresholds of seropositivity
using the mean plus two standard deviations of pre-challenge responses across 45 participants. For Etramp 4 Ag 2, the outlier at baseline (blue triangle) was
removed for the threshold calculation; the blue dashed line represents the threshold if the outlier at baseline was included.
5 Ag 1 at C+30, and 50% to MSP1-19 at C+115 (4/8). Addition of
one to two other antigenic targets for this low exposure category
at either time point included all participants with an antibody
response (see below for one non-responding participant).
Strong Correlation Between Cumulative
Parasite Density and Antibody Intensity
Responses up to seven SD greater than the mean of C−1 responses
were seen at C+30 for Etramp 5 Ag 1. Other targets associated
with high antibody levels at C+30 were GLURP-R2, MSP4 and
CSP (SD’s greater than five recorded). All participants showed a
minimum of one SD greater than the mean of C−1 responses for
GLURP-R2, while for all other antigens zero to negative responses
were seen in at least one of the participants (Figure 3B). Highly
reactive antigens at C+30 were those associated with median
responses over arbitrary thresholds of three SD (Top 2: Etramp
5 Ag 1 and GLURP-R2), two SD (Top 4: top 2, as well as MSP4
and MSP1-19) or one SD (Top 10: top 4 as well as GLURP-
R0, MSP5, SEA-1, CSP, Etramp 4 Ag 2, AMA1) greater than
the mean of C−1 responses (Table 2). Standardized antibody
responses to these top responding antigens were averaged to
represent overall antibody density at C+30 (Figure 3C) and C+115
(Figure 3D). Most individual antigenic targets showed moderate
correlation with parasite exposure (i.e., Spearman’s ρ = 0.50–0.69)
except for GLURP-R0 and CSP (not significant at p > 0.00125),
while MSP1-19 showed strong correlation (Spearman’s ρ = 0.86,
p < 0.001), see (Figure 4). Overall antibody density of top
responding antigens showed a strong correlation with cumulative
parasite density at C+30 (all 40 antigens: Spearman’s ρ = 0.51,
while top 4 responding antigens Spearman’s ρ = 0.82; p < 0.001)
and C+115 (all 40 antigens: Spearman’s ρ = 0.50, while top 4
responding antigens Spearman’s ρ = 0.78; p< 0.001).
Participants With Limited Antibody
Response
One participant had no demonstrable IgG to any of the 40
malarial antigens tested in samples at either of the post-challenge
time points, though tetanus toxoid responses were recorded (log-
transformed MFI-bkg values over 7.9 across both time points).
For participants with serum samples available at both post-
challenge time points, two other participants had an antibody
response to only one of the forty antigens at either the C+30 or the
C+115 time point (to CSP or GLURP-R2). The total proportion
of individuals with no detectable IgG antibodies at C+30 was
therefore 4.4% (2/45) and at C+115 6.5% (2/31). These three
participants were in the lowest category of cumulative parasite
density and had peak parasite densities ≤0.20 parasites/µl.
DISCUSSION
Controlled human malaria infection trials provide unique
opportunities to study immune responses after exposure
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FIGURE 3 | The number of antigenic targets recognized at three time points (A), standardized antibody responses (B) and averaged standardized antibody
responses (C,D). In (A,C,D) results are shown over tertiles of cumulative parasite density (expressed as the log-transformed area under the curve for parasite density
versus time until, and including the day of treatment). In (A) results are further categorized over time points post-challenge. An antigen is considered recognized if
antibody responses (expressed as log-transformed median fluorescence intensity corrected for background reactivity) were higher than the mean plus two standard
deviations (SD) of pre-challenge responses across 45 participants (i.e., seropositive). In (B–D) antibody responses were standardized by subtracting the mean of
pre-challenge responses across 45 participants and dividing by its SD. In (B) standardized antibody responses 30 days post-challenge are ordered by median
reactivity on the x-axis. Dashed lines represent arbitrary thresholds at 1 SD (red – top 10 antigenic targets), 2 SD (green – top 4 antigenic targets) or 3 SD (blue – top
2 antigenic targets) greater than the mean of pre-challenge responses. In (C,D) standardized antibody responses to antigens with a median above these arbitrary
thresholds were averaged and are shown 30 days (C) and 115 days (D) after challenge, using the same color scheme. Average responses across all 40 targets are
shown in black.
to a known number of malaria-infected mosquitoes and
an accurately quantified parasite exposure (Sauerwein
et al., 2011; Scholzen and Sauerwein, 2016). We measured
antimalarial antibody (IgG) responses in previously malaria
naïve individuals from eight CHMI studies using a custom-made
protein microarray. We showed that low parasite densities
generated detectable IgG responses in 96% of the participants
1 month after challenge, and in 94% two to 7 months after
challenge. Even at the low parasite densities recorded in
these participants, a strong correlation was seen between
cumulative parasite density and the number of antigenic
targets recognized as well as the intensity of IgG responses.
Immune responses to a subset of proteins including one
hypothesized to be associated with recent exposure were
developed by nearly all individuals (i.e., GLURP-R2, MSP1-
19 and Etramp 5 Ag 1). It is an important observation
that exposure to these infections was detected considering
the low parasite density range, which would probably have
remained undetected by routine microscopy or rapid diagnostic
tests (i.e., 50/54 participants had peak parasite densities
<100 parasites/µl while all remained <200 parasites/µl)
(Wongsrichanalai et al., 2007; Okell et al., 2009; Wu et al.,
2015).
We assessed IgG reactivity to forty purified recombinant
antigens of the P. falciparum parasite. All targets were associated
with the erythrocytic stage of the parasite life cycle, except for
one pre-erythrocytic target (CSP). GLURP-R2, Etramp 5 Ag 1,
MSP4 and MSP1-19 were associated with the highest relative
antibody responses. Seroprevalence 1 month post-challenge was
highest for GLURP-R2 (91%) and Etramp 5 Ag 1 (82%), dropping
to approximately two-thirds seropositive two to 7 months post-
challenge. Etramp 5 Ag 1 was associated with the highest antibody
levels 1 month after challenge relative to pre-challenge responses.
This antigen was one of the targets highlighted as a potential
marker of recent exposure in a cohort of Ugandan children (Helb
et al., 2015). Likewise, GLURP-R2 was associated with recent
exposure in a Cambodian population (Kerkhof et al., 2016).
Although we were unable to assess the rate of antibody decay
in this study due to the small sample size, the low number
of individuals with repeated samples and limited follow up
time, high reactivity is evident in this previously non-exposed
population. Other hypothesized markers of recent exposure
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TABLE 2 | Characteristics of the top 10 antigenic targets associated with the highest antibody responses 30 days post-challenge in controlled human malaria infection
participants.
Gene ID Description Name Allele Locationa AA
position
Expression
tag
Reference
PF3D7_0532100 Early transcribed membrane
protein 5
Etramp 5 Ag 1 3D7 iRBC/PVM 26–111 GST Spielmann et al., 2003;
Tetteh, unpublished
PF3D7_1035300 Glutamate rich protein R2 GLURP-R2 F32 Merozoite (Peripheral) 705–1178 Hisx6 Theisen et al., 1995
PF3D7_0207000 Merozoite surface protein 4 MSP4 D10 Merozoite surface
(GPI-anchored)
43–107 GST Marshall et al., 1997
PF3D7_0930300 19 kDa fragment of the
merozoite surface protein-1
MSP1-19 Wellcome Merozoite surface
(GPI-anchored)
1631–1726 GST Burghaus and Holder,
1994
PF3D7_0423700 Early transcribed membrane
protein 4
Etramp 4 Ag 2 3D7 iRBC/PVM 76–136 GST Spielmann et al., 2003;
Tetteh, unpublished
PF3D7_1035300 Glutamate rich protein R0 GLURP-R0 F32 Merozoite (Peripheral) 94–489 Hisx6 Theisen et al., 1995
PF3D7_0206900 Merozoite surface protein 5 MSP5 3D7 Merozoite surface
(GPI-anchored)
147–207 GST Marshall et al., 1998
PF3D7_1021800 Schizont egress antigen 1 SEA-1 3D7 Schizont/Maurer’s cleft 810–1083 GST Raj et al., 2014; Tetteh,
unpublished
PF3D7_0304600 Circumsporozoite protein CSP 3D7 Sporozoite surface 20–373 n/a Kastenmüller et al.,
2013
PF3D7_1133400 Apical membrane antigen 1 AMA1 FVO Sporozoite/Merozoite
(Micronemes)
97–546 Hisx6 Collins et al., 2007
GPI, glycosylphosphatidylinositol; PVM, parasitophorous vacuolar membrane; iRBC, infected red blood cell; GST, glutathione S-transferase; kDa, kilodalton; AA, amino
acid. aLocation information is based on published literature and mass spec proteomic data (plasmodb).
identified by Helb et al. (2015) were also recognized in this
population (42% for CSP and 27% for Etramp 4 Ag 2 1 month
post-challenge), whereas HSP40 and GEXP18 were not (<5%).
At 2–7 months after challenge, MSP1-19 was associated with the
highest seroprevalence (84%; 27/32). This target also showed the
strongest correlation with cumulative parasite density 1 month
post-challenge (Spearman’s ρ = 0.86, p < 0.001). MSP1-19 has
been associated with changes in transmission over time (van den
Hoogen et al., 2015) and in recent transmission (Supargiyono
et al., 2013). MSP4 was the final target in the top four responding
antigens 1 month after challenge, while MSP5 was in the top 10.
These antigens were associated with protection against clinical
disease in Senegalese (Perraut et al., 2017), Brazilian (Medeiros
et al., 2013), and Vietnamese (Wang et al., 2001) populations
and warrant further investigation. MSP4 was also strongly
associated with recent asymptomatic and symptomatic infections
in Kenyan children alongside AMA-1, MSP1-19, and EBA140 RII
(McCallum et al., 2017).
Previous studies describing antibody responses to malaria in
CHMI participants concluded that a single CHMI is sufficient
to induce production of antibodies directed against sporozoite,
liver-stage and cross-stage antigens (Scholzen and Sauerwein,
2016). In line with our current findings, the magnitude of
antibody and memory B-cell responses to cross-stage antigen
MSP1-19 was reported to correlate with the degree of parasite
exposure (duration and peak density) (Biswas et al., 2014;
Elias et al., 2014; Nahrendorf et al., 2014; Walker et al.,
2015). The majority of studies examining antibody responses
following CHMI focused on antibody responses related to
(sterile) protection and identified antigenic targets such as EXP-
1 (Obiero et al., 2015), LSA-1 (Felgner et al., 2013; Nahrendorf
et al., 2014), TRAP (Peng et al., 2016), and CSP (Felgner
et al., 2013; Nahrendorf et al., 2014; Obiero et al., 2015;
Hickey et al., 2016), showing some evidence for an increase
in responses with increasing parasite exposure. Only a limited
number of studies have reported antibody responses to multiple
malarial antigenic targets, other than CSP or AMA1 and MSP1-
19 alone, in the previously malaria naïve control groups of
CHMI trials (Turner et al., 2011; Obiero et al., 2015; Hodgson
et al., 2016). Obiero et al. (2015) and Hodgson et al. (2016)
assessed antibody responses after CHMI in both non-endemic
and endemic populations using ELISA (Hodgson et al., 2016).
Seropositivity against MSP1-19, Rh5, CSP, and LSA-1 were
similar to those we recorded. However, seropositivity against
AMA-1 was considerably higher (Hodgson et al., 2016) or non-
existent (Obiero et al., 2015), compared to moderate responses
in our study. These differences may be due to differences
in assay protocols, strains used [3D7 (Hodgson et al., 2016)
versus FVO] or the levels of parasite exposure. In both studies,
antimalarial antibody responses were induced more efficiently in
endemic volunteers compared to non-endemic volunteers, even
if baseline responses were the same, indicating the presence of
memory B cells in endemic populations (Wipasa et al., 2010).
Burel et al. (2017) reported that the generation of antibodies
to blood-stage antigens following CHMI is strongly influenced
by expression patterns of microRNA, which are involved in
regulation of immune responses, and that microRNA expression
patterns vary considerably between individuals. Turner et al.
(2011) explored antibody responses to (multiple regions of)
five blood-stage antigenic targets in volunteers from a Dutch
CHMI trial using a multiplex bead assay. They found responses
in 93% of volunteers 35 days post-challenge, mostly against
PfEMP1 (which was not included in our panel) and GLURP-
R2, with lower seropositivity against GLURP-R0 and MSP3,
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FIGURE 4 | The association between cumulative parasite density and standardized antibody responses. Cumulative parasite density is expressed as the
log-transformed area under the curve for parasite density versus time until, and including the day of treatment. Antibody responses (expressed as log-transformed
MFI corrected for background reactivity) 30 days post-challenge were standardized by subtracting the mean of pre-challenge responses across 45 participants and
dividing by its standard deviation (SD). In (A–J) Spearman’s ρ and associated p-values are shown per antigen. Solid lines and shaded areas are fractional polynomial
fits with 95% confidence intervals. In (K,L) standardized antibody responses against antigenic targets with a median above arbitrary thresholds of 1 SD (red – top 10
antigenic targets), 2 SD (green – top 4 antigenic targets) or 3 SD (blue – top 2 antigenic targets) greater than the mean of pre-challenge responses, were averaged.
Average responses across all forty targets are shown in black. In (K) Spearman’s ρ for all 40: 0.51, top 10: 0.77, top 4: 0.82, top 2: 0.61; p < 0.001 and in (L) all 40:
0.50, top 10: 0.69, top 4: 0.78, top 2: 0.72; p < 0.001.
similar to our results. They saw no association between PfEMP1
antibody acquisition and parasite load or maximum parasite
density (Turner et al., 2011). The strong correlations seen
in the current cohort are most likely due to the increased
range in parasite exposure. In addition to the overlap in these
previously described results, we show responses to a range of
erythrocytic antigens including those potentially associated with
recent infection using a newly developed custom-made protein
microarray.
Studying antibody responses following malaria infections
in volunteers from non-endemic areas is informative due
to difficulties in assessing the exact level and frequency
of previous exposure in endemic populations. Genetic and
environmental differences between malaria endemic and non-
endemic populations make direct translation of these results
challenging. Moreover, parasite densities are likely to reach
considerably higher levels in natural infections, which in turn
would influence the number of antigenic targets recognized and
the intensity of existing responses. Nevertheless, an overlap was
seen between our results and those from endemic populations for
certain antigenic targets [Etramp 5 (Helb et al., 2015), Etramp
4 (Helb et al., 2015), CSP (Baum et al., 2013; Helb et al., 2015),
MSP4 (Baum et al., 2013; Burel et al., 2017; McCallum et al.,
2017), MSP1-19 (McCallum et al., 2017) and to a lesser extent
in our results AMA-1 (Stanisic et al., 2015; McCallum et al.,
2017)], while not for other targets [GEXP18 (Helb et al., 2015),
HSP40 (Helb et al., 2015), EBA140, EBA175, and MSP2 (Stanisic
et al., 2015; Burel et al., 2017; McCallum et al., 2017]). Overall,
it is an important observation that antibody responses could
be detected in a previously non-exposed population following
such low-density infections. The duration of detectable antibody
titres in the current study population, especially after re-infection,
is unknown. This information is of use for validation of these
targets in sero-surveillance aiming to generate proxy estimates
of incidence for transmission monitoring. Further assessment of
antibody kinetics following infection (i.e., assessing time since
infection) using these antigenic targets is essential. Although all
participants were previously naïve for malaria, we saw reactivity
to some of the included targets at the pre-challenge time point
(i.e., Etramp 4 Ag 2) potentially due to cross-reactivity with
antigens from other pathogens. Likewise, responses to AMA1 and
MSP1-19 were seen in some of the malaria naïve United Kingdom
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adults pre-challenge at similar concentrations to those detected at
C+30 (Hodgson et al., 2016). Using a two-standard deviation rule
to define the threshold of positivity has its limitations; by default,
this will cause some participants to be defined as seropositive pre-
challenge (i.e., approximately 2.5%). One participant remained
undetected for IgG responses against the panel of 40 antigens
evaluated. This may be due to the very low exposure to malaria
parasites as their peak parasite density was the lowest recorded
(0.15 parasites/µl) and the duration of their infection as detected
by qPCR was 1 day. Two other participants with limited antibody
responses recorded (i.e., to one of the antigens in the panel
at only one of the time points) had peak parasite densities of
≤0.20 parasites/µl. Furthermore, the panel of targets evaluated
is finite and there may be antigens not yet expressed that would
have induced a detectable immune response in these participants.
Lastly, IgM responses were not evaluated in this study, which may
also have been present in these participants.
CONCLUSION
Antibody responses to erythrocytic antigens were detectable
following low-density experimental P. falciparum infections in
nearly all volunteers. This included antigenic targets potentially
related to recent infection (Helb et al., 2015) as well as well-
known targets such as AMA1, MSP1-19, and CSP. Detecting
exposure to recent infections below the detection limit of
conventional diagnostics is essential to interrupt transmission
(Ouédraogo et al., 2016; malERA Refresh Consultative Panel
on Characterising the Reservoir and Measuring Transmission,
2017), especially in low transmission and elimination settings
where the majority of infections are of low-density (Okell et al.,
2009; Wu et al., 2015). We showed a strong dose-response
relationship between cumulative parasite density and antibody
density across multiple targets. Moving forward, a selection of
4–5 targets could be combined in a field-based assay such as
an ELISA to rapidly assess remaining transmission in (near-)
eliminating settings. This would be advantageous compared to
measuring infection rates, as PCR-based techniques are more
costly and labor-intensive, require larger sample sizes in low
transmission settings, are more sensitive to fluctuations in
parasite densities during an infection and overall rates between
seasons. Ultimately, our findings require validation in endemic
populations to define the minimum set of antigens needed to
reliably detect exposure to natural infections.
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